澳大利亚研究人员发表在《生物精神病学》期刊上的最新研究表明，在20多岁和30多岁期间使用大麻的人精神病发作的年龄会明显提前1。这项荟萃分析共审视了149项研究、涉及超过71000人的数据，挑战了延迟至20多岁使用大麻更为安全的普遍观点1。
研究发现，大麻使用与精神病发作年龄提前平均2.5年相关1。在30岁或以上才发病的患者中，这一差异更加显著，增加到6.3年1；而在20多岁后期发病的大麻使用者中，发病则平均提前4.4年1。值得注意的是，研究人员在20岁前发病的患者中未发现精神病发作提前的证据1。
精神病影响澳大利亚约0.5%的人口1，而超过250万澳大利亚人每年使用处方或非法大麻1。大麻的主要活性成分是四氢大麻酚(THC)1。40年的研究一致显示大麻与精神病之间存在关联1。
Australian researchers have published new findings challenging the assumption that delaying cannabis use until the 20s and 30s represents a safer approach. A meta-analysis examining 149 studies involving more than 71,000 people, published in Biological Psychiatry, revealed that cannabis use is associated with an earlier onset of psychosis in vulnerable individuals 1.
The research found that cannabis use correlates with psychosis onset occurring an average of 2.5 years earlier overall 1. The effect becomes more pronounced at older ages: among those diagnosed at age 30 or older, cannabis use was linked to psychosis onset being brought forward by 6.3 years 1. For late-20s onset cases, the average advancement was 4.4 years 1. Notably, the study found no evidence of accelerated psychosis onset among those who developed the condition before age 20 1.
Approximately 0.5% of Australians are affected by psychosis 1, while over 2.5 million Australians use prescription or illicit cannabis annually 1. Cannabis's primary active component is tetrahydrocannabinol (THC) 1. Four decades of research have consistently demonstrated an association between cannabis and psychosis 1.
评论
还没有评论，欢迎留下第一条。